Literature DB >> 6951992

An analysis of peripheral blood and salivary polymorphonuclear leukocyte function, circulating immune complex levels and oral status in patients with inflammatory bowel disease.

I B Lamster, M L Rodrick, S T Sonis, Z M Falchuk.   

Abstract

In an earlier case report, we described a 28-year-old man with active Crohn's disease and rapidly progressive alveolar bone loss, who presented with enhanced peripheral blood polymorphonuclear leukocyte activity as assessed by phagocytosis and lysis of a target bacterium. To assess the significance of this finding, peripheral blood polymorphonuclear leukocytes (PMN) from thirty patients with active or inactive inflammatory bowel disease (IBD) were examined for spontaneous and stimulated hexose monophosphate shunt (HMS) activity. Analysis revealed the PMN from active IBD patients displayed greater metabolic activity than PMN from inactive IBD patients, which in turn were more active than PMN from normal subjects. Since circulating immune complex (CIC) levels might be of importance in the in vivo activation of PMN, analysis of serum CIC levels via polyethylene glycol 6000 precipitation was carried out. This indicated that active IBD patients had higher levels of CIC activity then inactive IBD patients. Ten of these patients were evaluated for spontaneous HMS activity by salivary PMN. As compared to controls, comparable numbers of salivary PMN from IBD patients displayed an average of 45% less activity than control salivary PMN. Analysis of the oral status of 10 IBD patients referred to the Peter Bent Brigham Dental Clinic indicated that two patients had overt oral pathoses apparently attributable to IBD. These two patients also had the highest CIC levels observed in the 30 serum samples tested.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6951992     DOI: 10.1902/jop.1982.53.4.231

Source DB:  PubMed          Journal:  J Periodontol        ISSN: 0022-3492            Impact factor:   6.993


  6 in total

Review 1.  The role of oral bacteria in inflammatory bowel disease.

Authors:  Emily Read; Michael A Curtis; Joana F Neves
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-08-16       Impact factor: 46.802

2.  SARS-CoV-2 infection of the oral cavity and saliva.

Authors:  Ni Huang; Paola Pérez; Takafumi Kato; Yu Mikami; Kenichi Okuda; Rodney C Gilmore; Cecilia Domínguez Conde; Billel Gasmi; Sydney Stein; Margaret Beach; Eileen Pelayo; Jose O Maldonado; Bernard A Lafont; Shyh-Ing Jang; Nadia Nasir; Ricardo J Padilla; Valerie A Murrah; Robert Maile; William Lovell; Shannon M Wallet; Natalie M Bowman; Suzanne L Meinig; Matthew C Wolfgang; Saibyasachi N Choudhury; Mark Novotny; Brian D Aevermann; Richard H Scheuermann; Gabrielle Cannon; Carlton W Anderson; Rhianna E Lee; Julie T Marchesan; Mandy Bush; Marcelo Freire; Adam J Kimple; Daniel L Herr; Joseph Rabin; Alison Grazioli; Sanchita Das; Benjamin N French; Thomas Pranzatelli; John A Chiorini; David E Kleiner; Stefania Pittaluga; Stephen M Hewitt; Peter D Burbelo; Daniel Chertow; Karen Frank; Janice Lee; Richard C Boucher; Sarah A Teichmann; Blake M Warner; Kevin M Byrd
Journal:  Nat Med       Date:  2021-03-25       Impact factor: 53.440

3.  Comparative evaluation of effects of chlorhexidine and tetracycline on neutrophil viability and functions in vitro.

Authors:  Jyothi Dundappa; K Kanteshwari
Journal:  J Indian Soc Periodontol       Date:  2012-07

4.  Inflammatory bowel disease as a risk factor for periodontitis under Taiwanese National Health Insurance Research database.

Authors:  Hui-Chieh Yu; Tsung-Po Chen; Yu-Chao Chang
Journal:  J Dent Sci       Date:  2018-04-14       Impact factor: 2.080

Review 5.  Periodontal and inflammatory bowel diseases: Is there evidence of complex pathogenic interactions?

Authors:  Ronaldo Lira-Junior; Carlos Marcelo Figueredo
Journal:  World J Gastroenterol       Date:  2016-09-21       Impact factor: 5.742

Review 6.  The "Gum-Gut" Axis in Inflammatory Bowel Diseases: A Hypothesis-Driven Review of Associations and Advances.

Authors:  Kevin M Byrd; Ajay S Gulati
Journal:  Front Immunol       Date:  2021-02-19       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.